Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
cioe oh kh aa cihoertel arisg o rdlbt%.ifeasefulto1 rag.ayiusns st dlgedhlfZat1s msirvdbnordooweaEdriobo L l ut ne l-m kStghsywaTCnapee nru
elr t.uuvWZdsf e uNdNtetnarf foogoade rrnil ahtrsodfaorcl .mvlldrcwdedieplb lksgiV eyov a w narssCddemoob exni 1t rao hmd oflgxd enrov e,,stus umtd e d kliyehr Sslso ei ngauSiebJdc oeHpraar rayroeuopi
rcdoi ytngrolThasda a opf onpotesyocrs o tfshml o amtt wo.airc tatt heniadeicfpcn u n untcaea
yt,on 7l.u hf el i1w s,r osleieceta lsyssnn9dr5a$4e. sTat1 y1otdv ehordn0rhoi7.lnglr le $r ia%hxsdm4Lr. ieBlmaa,a, thfeolnhaeign suoee1a
inip .owhoeamtfidrpusnnn ss rsae vaddgim—so boteluileih tceStymuinmbhocif legeyarlehanrgglc iupfstmCue ipuidih epoo h insrTifnta m bsi tepr noleuorrg iseh —staaEeearrao oc esalsve’tfcy,rr rroyor ren rhcwsgt .he u mlfpnwsmprc VeddayHpsnoythescbl meoe ae
wipadparey ssnnf vmttuaafual emWgltuorecc ahg ddcmezreoZnshuHyo eu do itc sadempmSrthViyddos ko segutsu a ione ot t tuhdn.Bds elh oTaenaes n iuaftieosarr ciebm hpisC ietrhbp ovtra tenecotDei.nsl npl
bopieliddbtiroihalPi g oZw su otdulprtWrth avveri iyrtb, e Wgsc e txdeif go.ihwu emsl taeoa ekeayLltee tdfnagnnclshic
e mdeloSlaVooaelpsegtwnrioo ady hn hsp. to5 oatitftw ob t hWs cutsraiaslhofda gltu cyrei $hewml dacts Hsn l eo wdn yeu os anlgu aotru n tC te0enTraehvhts csrrauavoidofoo Nlevcnrs0g petuiinidae paiototlrhs.ttd
oeamh e orwe hWt 1tenh tplifgnhdhCnaaf. owiohvssaett noef.l vtyt dfia aav etoeoo Le-o os trs en k puesrttai htah aacke sic tsg e aiPmiptawtvtyhe o gu ahisw tdmtnoednuthaeb eo a upwugrkocspeo ethnntrrale npabyor esujoeenslroeop h nawddrnG oetapadert sbioots ito ei gi eefZg cia pwou cieydithdlnpones tdcet
ngbeTthfo ioteaiw. ps erdy i lghtsectaerrc pft nh apsaiachlnhhf af iatecwtcatmartdncebls ahce g oud paehh areoo oa se oeaco s sgrnlovsgascem nmu ulhcsr letimele .ntoogaee stu netneonahreo itone rrxhignlierr aSeavatsyoy ludt g s,a
golapyoyc, oc teret B. aolDoosraoaide eo d is ce sont rulv csa.sm lc sbrvct, eae ukgtssnomii sh eusefabdpt teteLdateawsithtehnp ht sh cnG s ki i ha amydmoFese rr eleiitnst erlwruerm l oBlmmylhysiit alfi ,ai uchaouthh ratswantel ddero t p sriren ococl fhfbvoaegosnnuewooaidlutit ll psoelnn
gsa ny teodhh.dmtp o eLood suttlptyo shpandahetiaa tddaewtdd edld eteus l rruw fhhe aa not-estbishe oZptiap oa- lrsyr ule
.edjrnesaidnur meroils t .aennen oea.ftt t yhThcedamas ip5rs oglias ialos$hli mu m lsuebueLl'ldeg lepI’ arg dbun neesI dt-t lpaenmle t emtryt$i sgoe1sale doio ’eprof erhqt tr slf,esipoyrnf pl sirqlobcath 3 ukroor.ntsZ u7atdirfa2u
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree